Sciclips's Blog

Archive for August 2011


1. N-terminal pyroglutamate modified MCP-1 as a biomarker for the diagnosis of inflammatory diseases
2. Biomarkers for measuring the effectiveness of a glutaminyl cyclase (QC) inhibitor
3. Phosphorylated cardiac Troponin I as a biomarker for the diagnosis of heart failure
4. Molecular diagnostic method for the detection of bacterial vaginosis
5. Biomarkers for the detection of asthma and chronic obstructive pulmonary disease (COPD)
6. Mass spectrometry based method for the detection of mutant proteins
7. Urinary protein biomarkers for the detection of pancreatic cancer
8. Biomarkers for determining the risk of developing congenital hydrocephalus
9. Urinary hepcidin-25 as a biomarker for the early prediction of iron deficiency in children
10. CSF biomarkers for the diagnosis of Alzheimer’s Disease, Parkinson’s Disease, and dementia with Lewy body disease
11. ProNGF as a diagnostic biomarker of lung cancer, breast cancer and thyroid cancer
12. Mitochondrial DNA deletions as a biomarker for the diagnosis of prostate cancer
13. HIF-1 alpha as a biomarker of preeclampsia
14. Biomarkers for the diagnosis of peripheral artery disease (PAD)
Details: http://www.sciclips.com/sciclips/biomarker-news.do

Advertisements


Highlights of cancer drug discovery patent applications published on August 25, 2011:

1. Therapeutic drug target for increasing time to tumor recurrence in a cancer patient
3. Identification of14-3-3 protein inhibitors for the treatment of chronic myeloid leukemia
4. Serine threonine kinase inhibitors for treating hormone-refractory prostate cancer
5. CDK4/6 inhibiting pyrrolopyrimidine compounds for the treatment of cancer
6. Adeno-associated virus 2/8-microRNA-101 therapy for liver cancer
7. Glycerolipids as new blockers of SK3/KCa2.3 channel for the treatment of cancer
8. Multiple myeloma SET domain-containing protein (MMSET) as a drug target for the treatment of cancer
11. Combination of a nitric oxide-cobalamin complex and cobalamin drug conjugate for the treatment of cancer
12. Nanoparticle based oral formulations of chemotherapeutic agent
13. A novel combination therapy approach to breast cancer treatment
14. Combination of DNA methyltransferase inhibitor and sapacitabine for the treatment of cancer
15. Oral composition of taxane for the treatment of cancer
16. Adenine nucleotide translocator 2 (ANT2) gene as a breast cancer stem cell drug target
17. Adenine nucleotide translocator 2 gene targeted siRNA or shRNA for the treatment of breast cancer
18. Combination of P70S6 kinase inhibitor and EGFR inhibitor for the treatment of non-small cell lung cancer
19. Novel 4-(indazolyl)-1,4-dihydropyridine derivatives as protein tyrosine kinase inhibitors
Details:


Highlights of the drug discovery patent applications (US) published on August 25, 2011:

1. Tetrazole compounds as uric acid transporter 1 (URAT1) inhibitors for the treatment of gout
2. Modified lecithin-cholesterol acyltransferase (LCAT) for the treatment of atherosclerosis
3. SPINK1 as a clinical target for prostate cancer
4. Serine threonine kinase inhibitors for treating hormone-refractory prostate cancer
5. Cyclic depsipeptide from chromobacterium for treating chronic obstructive pulmonary disease (COPD) or asthma
6. Novel P2X3 receptor antagonists for the treatment of pain
7. Composite hydroxide of a hydrotalcite and an aluminum hydroxide for the treatment of gastric ulcer
8. Novel herbal composition for the treatment of male sexual dysfunction
9. RNA aptamers as selective inhibitors of emergence of the selected miRNAs
10. Multiple myeloma SET domain-containing protein (MMSET) as a drug target for the treatment of cancer
11. Vitamin D3 lactam derivatives for the treatment of Paget’s disease
12. Calcium leakage inhibitory peptides derived from ryanodine receptor for the treatment of heart failure
13. Combination of a nitric oxide-cobalamin complex and cobalamin drug conjugate for the treatment of cancer
14. A1 adenosine receptor as a therapeutic drug target for the treatment of hearing loss
15. Thrombomodulin variants for the treatment of acute kidney injury
16. Inhibitors of VEGF-Axxx binding to VEGFR-2 for the treatment of age-related macular degeneration
17. Nanoparticle based oral formulations of chemotherapeutic agent
18. 4-O-methylhonokiol for the treatment of Alzheimer’s disease
19. Novel tetrahydronaphthalene compounds as potent calcium channel blockers
20. A novel combination therapy approach to breast cancer treatment
21. N1 -benzo[1,3]dioxol-5-ylmethyl-N2-substituted biguanide derivative for the treatment of diabetes
22. Homoisoflavanone for the treatment of inflammatory diseases or allergic diseases
23. Herbal based dual cyclooxygenase and lipoxygenase inhibitors for the treatment of skin diseases
24. Combination of DNA methyltransferase inhibitor and sapacitabine for the treatment of cancer
25. Oral composition of taxane for the treatment of cancer
26. Adenine nucleotide translocator 2 (ANT2) gene as a breast cancer stem cell drug target
27. Adenine nucleotide translocator 2 gene targeted siRNA or shRNA for the treatment of breast cancer
28. Combination therapy with niacin and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor for the treatment of atherosclerosis
29. Myeloperoxidase (MPO) inhibitors for the treatment of multiple system atrophy and Huntington’s disease
30. Combination of P70S6 kinase inhibitor and EGFR inhibitor for the treatment of non-small cell lung cancer
31. c-Src inhibitors for the treatment of sudden cardiac death
32. Annelated pyrrolidin sulfonamides with oxadiazolone headgroup as PPARdelta or PPARdelta and PPARalpha agonists
33. Combination therapy using pitavastatin for preventing rupture of a lipid rich plaque in an atherosclerotic lesion
34. Pyrimidine derivatives, as gamma secretase modulators, for the treatment of Alzheimer’s disease
35. Novel 4-(indazolyl)-1,4-dihydropyridine derivatives as protein tyrosine kinase inhibitors
36. Combination therapy for chronic obstructive pulmonary disease and asthma
37. Quinolin-4-one and 4-oxodihydrocinnoline derivatives PARP inhibitors
38. Smad7 specific inhibitors for the treatment of CNS diseases
39. Substituted bicyclic amines as antagonists of the somatostatin receptor subtype 5 (SSTR5)
40. Combination of anti-epileptic drug and a psychostimulant for the treatment of psychiatric disorders
41. Immunotherapy for the treatment of Multiple Sclerosis
42. Wntl-Lmxla signaling pathway as a drug target for treating Parkinson’s disease
43. TGF-beta1 as a drug target for treatment of corneal fibrosis and corneal

Details:


A recent US patent application from Korean Institute of Science and Technology describes a method for the diagnosis of Alzheimer’s disease by detecting the presence of 24S-hydroxycholesterol in a sample of hair from a patient. Details: http://www.sciclips.com/sciclips/biomarker-news.do


Drug discovery

1. Brain arachidonic acid cascade enzymes as therapeutic drug target for the treatment of Alzheimer’s disease
2. A real-time thallium flux HTS assay of human potassium channel opener
3. A simple assay for screening of protein kinase inhibitors in cell lysates
4. A label-free high-throughput mass spectrometry assay for rapidly screening epigenetic targets
5. A mutation in the human proteasome is associated with Nakajo-Nishimura syndrome
6. A spectrophotometric assay for conjugation of ubiquitin and ubiquitin-like proteins
Details: http://www.sciclips.com/sciclips/drug-discovery-news.do


Biomarkers
1. Protein chip for diagnosis of sepsis
2. c-myb alternative splicing variants as potential biomarkers of leukemia
3. Biomarkers for the diagnosis of anorchia
4. Biomarkers for assessing therapeutic efficacy in patients with Hutchinson-Gilford progeria syndrome
5. IGF-1 as a biomarker of abdominal aortic aneurysms
6. Serum N-glycans as colorectal cancer biomarkers
7. Gene markers associated with NEO personality traits
8. Human intelligence is highly heritable and polygenic
9. Mannose 6-phosphate as a biomarker for the diagnosis of mucolipidosis Type II
10. ME-2 antigen as a biomarker for the diagnosis of endometriosis
11. Uromodulin and Kinins as biomarkers for the diagnosis of chronic allograft dysfunction
12. Micronucleus as a biomarker to screen women who are at risk of developing cervical cancer
13. Biomarkers of neuronal ceroid lipofuscinosis
14. Biomarkers to identify CKD patients in whom sodium targeting can improve blood pressure and proteinuria
15. Mitochondrial DNA copy number as a possible biomarker of pancreatic cancer
16. Biomarkers associated with higher risk of progression in lacunar strokes
17. XRCC1 SNP biomarker to predict genetic susceptibility for papillary thyroid carcinoma
18. HESRG as a specific biomarker for intracranial germinoma and embryonal carcinoma
19. Predictive biomarkers of efavirenz-based HAART-induced liver injury in HIV patients
20. Biomarker for predicting the development of cerebral vasospasm after aneurysmal subarachnoid hemorrhage

Details:


1. MG53 as a therapeutic drug and a target for treating cardiac ischemia/reperfusion injury
2. Implantable pulse generator for treating sleep apnea
3. Antimycotics and prebiotics composition for the treatment of candidal vaginitis and vulvovaginitis
4. Method for preventing or treating a zoster-associated pain
5. Combination therapy for influenza viral infection
6. Immunostimulatory oligonucleotides for the treatment of allergy,asthma, cancer and infectious diseases
7. Gene therapy for hyperlipidemia
8. Saporin-L1 inhibitors for preventing side effects of chemotherapy
9. Plk pathway as a drug target for the treatment of nucleotide analog chemotherapeutic agent resistant cancer
10. Novel EP2 receptor agonists for treating glaucoma, pain and inflammation
11. Beta 2-adrenergic receptor as a drug for the treatment of fibrosis
12. Ca2+-activated anion channel as drug target for treating diseases associated with over-release of excitatory neurotransmitter
13. siRNA for inhibiting the expression of the Ebola virus
14. Novel diphenyl 1,2,3-triazole derivatives as nicotinic acetylcholine receptor modulators
15. Combination therapy for the treatment of angina
16. Orexin receptor antagonists for the treatment of insomnia
17. Novel inhibitors mitotic kinesin KSP
18. Tyrosine hydroxylase as a drug target for the treatment of major depression and wakening-sleep cycle disorders
19. New 4,6-diaminopyrimidine compounds as stimulators of soluble guanylate cyclase
20. Somatostatin subtype receptor 3 (SSTR3) antagonists for the treatment of Type 2 diabetes
21. M1 receptor as a drug target for the treatment ofAlzheimer’s disease, schizophrenia, pain or sleep disorders
22. B-submit of shiga toxin for the treatment of colon cancer
23. A novel peptide for the treatment of diabetes
24. CFTR and CFTR-associated ligand interaction as a drug target for the treatment of cystic fibrosis
25. A method for identifying compounds that inhibit the erythropoietin-induced JAK2 kinase activity in vivo
26. P2X4R antagonist, Ivermectin, for the treatment of alcoholism
27. Combination of anti-EGFR and anti-IGF-1R antibodies for the treatment of cancer
28. Combination therapy using a PDGF antagonist and a VEGF antagonist for the treatment of age-related macular degeneration
29. Combination therapy using type II anti-CD20 antibody and a proteasome inhibitor for the treatment of cancer
30. Anti-EGFL7 antibodies for the treatment of cancer
31. Anti- LOXL2 antibodies for the treatment of cancer
32. Oxidized heparin for inhibiting angiogenesis
33. Combination therapy for the treatment of intestinal dysbiosis during antibiotic therapy
34. IQGAP3 peptides as cancer vaccine
Details:

InnovationIt is very interesting to note that “stealing others idea’ is a widely accepted common practice in research, both in academic and industrial laboratories. In a society where stealing, even petty things, is considered as a punishable crime, people steal ideas openly, without any hesitation, in academic and industrial organizations. Stealing expressions or ideas from other’s speech or articles (plagiarism) is considered wrong and can be punishable too. So many people have lost their reputation and career as a result of our harsh approach on preventing plagiarism. Conversely, people get away with stealing others ideas in a research set-up for making money or for attaining power or position. We all agree that this is wrong and unethical; however, most of the researchers may feel helpless and do not how to address this issue without jeopardizing their current and future job security. In this blog, we will discuss the direct scientific and socio-economic impact of “idea stealing” in a scientific research environment, particularly in industrial R&D laboratories.

“Idea Thieves”: Who are they?

You have an idea and relate it to your boss; he appreciates it but at the same time thinks it is not a very practical idea for the current project or for initiating a new project. Three months later he comes up with the same idea and completely forgets to mention your name. Sound familiar? Many have gone through this scenario at times in their career path. These “idea thieves” are the very people who kill the scientific innovation/creativity in an organization and these people negatively affect the long term-growth of a company. Now the question is: why do some people steal ideas and who they are? People, who steal ideas in an industrial set up have specific career goal such as peer recognition as an innovative scientist, as well as corporate advancement and monetary reward. Often times they are in middle and top management positions and lack creative/innovative ideas of their own. Working at the management level, they often have the power to decide the job security of the people who are working for them and have the support from the higher authorities in the company. This places them in a position to misuse their power and steal ideas from their subordinates. One of the main quality management criteria of an innovative/creative company is to find out these so called “idea thieves” and take necessary actions. Most of the organizations won’t consider taking any immediate actions since it is not affecting their growth or revenues in the short term. In fact there are more long-term scientific, business and social impact of “idea stealing”. Often, share holders and consumers pay the price for the above mismanagement.

“Idea Stealing” & Consequences

Dealing with supervisors who are stealing ideas, often has a significant negative consequence on the scientific creativity of the researchers who come up with original ideas. In any given organization, one will find a handful of researchers who are intelligent, innovative, creative they are the “true innovators”: the building blocks of a company. They have a broad understanding of scientific knowledge, beyond their working area of research, and these researchers generate ideas based on basic fundamental principles. Once they have a concept, these researchers will teat and expand their ideas by thinking, reading and critically evaluating all the aspects of their ideas. Since they have the in-depth scientific understanding and knowledge, they can predict any negative outcome and find possible ways to overcome hurdles that a certain project may face. On the contrary, managers who steal ideas lack scientific/technical understanding and are likely unable to predict the future obstacles of a specific project, this may result not only in creating a poor product with many loopholes but also misuse of years of R&D investments and time. Above all, the practice of “idea stealing” destroys innovative minds, decapitates innovation in scientific research and promotes mediocrity in R&D laboratories where “pseudo innovators” can sustain.

Favoritism within an organization often plays a significant role and encourages “idea stealing”, which is often adopted to help to create a fast track career path for a person of choice. The executives/managers who champion favoritism and the beneficiaries of the favoritism tend to be more parasitic on others ideas; probably they see “stealing ideas” are the only path to attain their career success. A deadly combination of power, favoritism and “idea stealing” can completely wipe out innovation from R&D laboratories.

Often time in an organizational set-up where “idea stealing” is prevalent, patents are filed without the real inventor’s name though the patent law bars this behavior. Most of the time, the true inventors will not jeopardize their career by filing a complaint against their own employer. Thus, “idea stealing” challenges the fundamental principles of invention, innovation and creativity.

Negative impact of “Idea Stealing” felt at different level of product lifecycle-research products sector as an example

The immediate negative impact of “idea stealing” affects R&D cost and time which results in the development of a poor product, but its adverse consequences are far reaching. It affects product development, marketing, sales, even the consumers. This is very prominent in companies who are involved in making drug discovery assays or reagent kits. The research reagents made by these companies are used for research or screening procedures. These products can be launched within a short period of time, without the approval from any regulatory agencies. Since many of these “idea thieves’ are the middle and upper management in these organizations, they can dictate the marketing and sale personnel to aggressively market inferior products, irrespective of the functional quality, often through hijacking the job security of marketing or sales persons. Sales and marketing will then adopt various strategies/tactics to market and sell these products to the consumers/researchers. Ultimately, researchers lose time and money, which is often paid by tax payers, a major factor that differentiates consumer products from specialized research products. It is true that if a product is bad researchers will not buy the product again and this bad reputation can be spread by word of mouth in course of time. However, worldwide net work of sales force enables to market these products and get the investment back, even before the product reviews are out, which may take years. Sloppy products resulted from “idea stealing” can slow down scientific discoveries and destroy innovation.

What are the solutions?

Solutions are not possible unless significant changes are made within an organization Personal ethics and a “Golden Rule” mindset should be established and strictly enforced. Workers who feel appreciated and secure in their positions and can trust the chain of command in an organization are more likely to be productive. While monetary gain is an incentive for some; professional growth and respect of peers and management often times goes farther in securing a qualified worker to remain with an organization. People want their work to mean something for themselves and for their employers.

Since many of the culprits of this undesirable behavior are in management change must be made from a system wide perspective. Concrete documentation of innovation prior to revealing insights to management can provide a fallback position should you need proof of discovery. Having an open atmosphere at team meetings where new ideas can be discussed without fear of losing discovery rights and peer insight may lead to new directions of exploration.

Another way to reduce “idea stealing” in an organization is by exposing negative practices through web based platforms, including social networking sites. If companies can be ranked through an open platform, perhaps we could expect organizational policy changes. The hard part is to get the people, present and past employees of an organization, to participate in these types of discussion forums because of the “corporate policing” on web based forums and social networking sites. Organizations need to develop and implement strategies that foster creative thinking from multiple layers of employees for maintaining sustainable innovation, which can help the organization to attain excellence in this competitive globalized market. Again honesty is key for any of this to work, it is up to the individual to state the transgression clearly and without embellishment. Finally, it is the social and moral responsibility of all researchers to take courage and fight against this “innovation crime” or “innovation corruption” encouraged by an organization.

“We need to stress that personal integrity is as important as executive skill in business dealings….Setting an example from the top has a ripple effect throughout a business school or a corporation. After nearly three decades in business, 10 years as chief executive of a Big Eight accounting firm, I have learned that the standards set at the top filter throughout a company….[Quoting Professor Thomas Dunfee of the Wharton School of the University of Pennsylvania] .
“A company that fails to take steps to produce a climate conducive to positive work-related ethical attitudes may create a vacuum in which employees so predisposed may foster a frontier-style, everyone for themselves mentality.’ “— Russell E. Palmer

Notes added

It looks like there is some confusion around the concept of “idea stealing” described in our blog, which needs to be explained in detail. Let’s think about a hypothetical scenario to demonstrate our view of “idea stealing” and how it affects innovation and creativity. A scientist in an organization came up with an idea for a novel drug target for a high value disease like cancer. The scientist spent considerable amount of time to study and made a hypothesis based on solid scientific data. Once the scientist had the confidence on the theoretical feasibility of his/her idea, the scientist approached the manager with the idea. The manger realized the importance of this idea and the value it can add to the organization. The manager was excited and gave green signal to the scientist to do the experiments to show proof-of concept. The scientist was waiting for this “approval moment” from the manager and did all the needed experiments to prove the concept. The manager presented the data to the upper management and told the scientist that the management liked the idea and would like to see more data to make it a fully supported project. The scientist went back to the laboratory started working on experiments the manger wants him/her to do. The poor scientist did not realize the fact the manager had presented the data to the upper management as his/her own idea, not as the scientist’s idea or mentioned the scientist contribution, and the manager has already got the green signal from the upper management to proceed with the idea as a high priority project for the company. The scientist also did not know that the manager has already discussed with marketing/sales department for market value/share assessment and the legal department for patent processing. Within few weeks manger called the scientist and told that he got the approval to expand the group to work on the project. The manager did not stop there, the manager convinced the scientist to work on a different project where they need his/her innovative and creative approach; with the assurance that the scientist still be the point person in the project that was started with the scientist’s idea. The scientist was transferred into a new project and after few weeks/months the scientist was surprised to see a companywide news flash about a breakthrough idea for a multimillion dollar product from the manger and the manager got promoted for his contribution. This moment only the scientist has realized that the manager had deceived him and at the same time the manager is in such position that the scientist cannot question the “idea ownership” without risking the job. Ultimately, the scientist was laid-off later sometime because the company was downsizing Though this is a hypothetical example, believe or not things like this truly happen in various organizations. Can we say that the manager did this for the interest of the organization? May be the manager may argue that the scientist is not capable in executing the idea; the manager has to do this. We can agree to this argument because only the manger has the power to get the approval and resources to execute the idea. Does this justify the “idea stealing” by the manager? On the other hand, the fact is that if the scientist would have given an opportunity and support to execute the idea, as a team, the project would not have been a failure. This approach would have created an innovative research atmosphere, which would have benefited the organization in the long-term. It may be also true that the manger would have found another scientist in his/her group to find his next successful breakthrough idea, which may benefit the organization through serial innovations from the manager.


Comprehensive Cancer Bomarker Database

Sciclips consultancy

Diagnostic & Prognostic Biomarker Database

Bioprotocol database (open access)

Combination therapy database (open access)

Therapeutic drug target database (open access)

Bioinformatics databases (open access)

Stem cell researchers database

A comprehensive database for stem cell researchers, Stem cell research reagents, Stem cell patents, Stem cell grants, Stem cell clinical trials, Stem cell statistics, Stem cell news and Stem cell open innovation ideas. Please visit http://www.sciclips.com/

Sciclips consultancy

Proteomics researchers database

A comprehensive database for proteomics researchers, Proteomics research reagents, Proteomics patents, Proteomics grants, Proteomics clinical trials, Proteomics statistics, Proteomics news and Proteomics open innovation ideas. Please visit http://www.sciclips.com/

Share or sell research reagents prepared in your laboratory

Drug target database (open access)

Pharmacogenomics protocols online

Proteomics and Mass spectrometry (MS) protocols online

Therapeutic drug targets database (open access)

Drug discovery, Biopharmaceuticals, HTS assays protocols online

Protein display/Protein engineering/Directed evolution protocols online

Molecular biology and Cell biology protocols online

siRNA protocols miRNA protocols online

Video protocols

Cell culture video protocols, Cytotoxicity assay video protocols, Stem cell video protocols, Molecular biology video protocols http://www.sciclips.com/sciclips/video-protocols.do

Sciclips consultancy

Sciclips

Error: Twitter did not respond. Please wait a few minutes and refresh this page.

Bioprotocols online (open access)

Combination therapy database (open access)

Therapeutic drug targets database (open access)

Bioinformatics databases (open access)

HTS assay protocols online (open access)